Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuebijing injection in peritonitis-induced sepsis
ChiCTR1900020593Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Yunnan Province
- Start
- Jan 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial of xuebijing in sepsis and peritonitis (2 arms), sponsored by The First People's Hospital of Yunnan Province. Primary endpoints: 28-day mortality and APACHE II score. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
xuebijing
03
Conditions
sepsisperitonitis
Beyond the preview
Go deeper on ChiCTR1900020593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020593.